Insulin treatment in cancer cachexia: Effects on survival, metabolism, and physical functioning

Clinical Cancer Research

Volumn 13, Issue 9, 2007, Pages 2699-2706

  Lundholm, Kent ^a   Körner, Ulla ^a   Gunnebo, Lena ^a   Sixt Ammilon, Petra ^a   Fouladiun, Marita ^a   Daneryd, Peter ^a   Bosaeus, Ingvar ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FATTY ACID; INDOMETACIN; INSULIN; RECOMBINANT ERYTHROPOIETIN; TUMOR MARKER;

AGED; ANEMIA; ARTICLE; BLOOD TESTIS BARRIER; BODY COMPOSITION; BODY FAT; CACHEXIA; CANCER PATIENT; CARBOHYDRATE INTAKE; CONTROLLED STUDY; DEMOGRAPHY; ENERGY EXPENDITURE; EXERCISE; FOLLOW UP; FOOD INTAKE; GASTROINTESTINAL MALFORMATION; HUMAN; MAJOR CLINICAL STUDY; METABOLISM; PALLIATIVE THERAPY; PARENTERAL NUTRITION; PHYSICAL ACTIVITY; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; REST; SURVIVAL; TUMOR GROWTH; WEIGHT REDUCTION;

AGED; BODY COMPOSITION; CACHEXIA; EXERCISE TOLERANCE; FEMALE; HUMANS; INSULIN; MALE; NEOPLASMS; SURVIVAL; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34249029380     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2720     Document Type: Article

References (51)

1. Simons JP, Schols AM, Buurman WA, Wouters EF. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond) 1999;97:215-23.
2. Lundholm K, Holm G, Schersten T. Insulin resistance in patients with cancer. Cancer Res 1978;38:4665-70.
3. Drott C, Waldenstrom A, Lundholm K. Cardiac sensitivity and responsiveness to β-adrenergic stimulation in experimental cancer and undernutrition. J Mol Cell Cardiol 1987;19:675-83.
4. Lundholm K, Daneryd P, Bosaeus I, Körner U, Lindholm E. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: effects on survival, metabolism and function. A randomized prospective study. Cancer 2004;100:1967-77.
5. Bing C. Insight into the growth hormone-insulin-like growth factor-I axis in cancer cachexia. Br J Nutr 2005;93:761-3.
6. Drott C, Svaninger G, Lundholm K. Increased urinary excretion of cortisol and catecholami-NES in malnourished cancer patients. Ann Surg 1988;208:645-50.
7. Persson H, Bennegard K, Lundberg PA, Svaninger G, Lundholm K. Thyroid hormones in conditions of chronic malnutrition. A study with special reference to cancer cachexia. Ann Surg 1985;201:45-52.
8. Fouladiun M, Körner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm K. Body composition and time course changes in regional distribution of fat and lean tissues in unselected cancer patients on palliative care - correlations with food intake, metabolism, exercise capacity and hormones. Cancer 2005;103:2189-98.
9. Huang Q, Zhang X, Jiang ZW, Liu BZ, Li N, Li JS. Hypoleptinemia in gastric cancer patients: relation to body fat mass, insulin, and growth hormone. JPEN J Parenter Enteral Nutr 2005;29:229-35.
10. Frost RA, Lang CH. Skeletal muscle cytokines: regulation by pathogen-associated molecules and catabolic hormones. Curr Opin Clin Nutr Metab Care 2005;8:255-63.
11. Garcia JM, Garcia-Touza M, Hijazi RA, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 2005; 90:2920-6.
12. Martin F, Santolaria F, Batista N, et al. Cytokine levels (IL-6 and IFN-γ), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999;11:80-6.
13. Lundholm K, Gelin J, Hyltander A, et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994;54:5602-6.
14. Lundholm K, Daneryd P, Korner U, Hyltander A, Bosaeus I. Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol 2004;24:505-12.
15. Daneryd P, Svanberg E, Korner U, et al. Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. Cancer Res 1998;58:5374-9.
16. Reich F. [Therapy of cachexia in cancer by insulin. Med Klin (Munich) 1952;47:936-7.
17. Hyltander A, Bosaeus I, Svedlund J, et al. Supportive nutrition on recovery of metabolism, nutritional state, health-related quality of life, and exercise capacity after major surgery: a randomized study. Clin Gastroenterol Hepatol 2005;3:466-74.
18. Bosaeus I, Daneryd P, Lundholm K. Dietary intake, resting energy expenditure, weight loss and survival in cancer patients. J Nutr 2002;132:3465-6S.
19. Harris JA, Benedict FD. A biometric study of basal metabolism in man. Philadelphia; JB Lippincott, 1919.
20. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
21. Hyltander A, Korner U, Lundholm KG. Evaluation of mechanisms behind elevated energy expenditure in cancer patients with solid tumours. Eur J Clin Invest 1993;23:46-52.
22. Lindholm E, Daneryd P, Korner U, Hyltander A, Fouladiun M, Lundholm K. Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients. Clin Cancer Res 2004;10:6855-64.
23. Hanby C, Matthews C, Wilcox S, DerAnanian C. Predictors of adherence to a home-based walking intervention in breast cancer survivors. Med Sci Sports Exerc 2004;36:S285-6.
24. Bennegard K, Eden E, Ekman L, Schersten T, Lundholm K. Metabolic balance across the leg in weight-losing cancer patients compared to depleted patients without cancer. Cancer Res 1982;42: 4293-9.
25. Lundholm K, Edstrom S, Karlberg I, Ekman L, Schersten T. Glucose turnover, gluconeogenesis from glycerol, and estimation of net glucose cycling in cancer patients. Cancer 1982;50:1142-50.
26. Bennegard K, Eden E, Ekman L, Schersten T, Lundholm K. Metabolic response of whole body and peripheral tissues to enteral nutrition in weight-losing cancer and noncancer patients. Gastroenterology 1983; 85:92-9.
27. Eden E, Edstrom S, Bennegard K, Schersten T, Lundholm K. Glucose flux in relation to energy expenditure in malnourished patients with and without cancer during periods of fasting and feeding. Cancer Res 1984;44:1718-24.
28. Holroyde CP, Skutches CL, Boden G, Reichard GA. Glucose metabolism in cachectic patients with colorectal cancer. Cancer Res 1984;44:5910-3.
29. Moley JF, Morrison SD, Norton JA. Insulin reversal of cancer cachexia in rats. Cancer Res 1985;45: 4925-31.
30. Bartlett DL, Charland S, Torosian MH. Growth hormone, insulin, and somatostatin therapy of cancer cachexia. Cancer 1994;73:1499-504.
31. Brauer M, Inculet RI, Bhatnagar G, Marsh GD, Driedger AA, Thompson RT. Insulin protects against hepatic bioenergetic deterioration induced by cancer cachexia: an in vivo 31P magnetic resonance spectroscopy study. Cancer Res 1994;54:6383-6.
32. Rofe AM, Bourgeois CS, Coyle P, Taylor A, Abdi EA. Altered insulin response to glucose in weight-losing cancer patients. Anticancer Res 1994;14:647-50.
33. Ogilvie GK, Walters L, Salman MD, Fettman MJ, Johnston SD, Hegstad RL. Alterations in carbohydrate metabolism in dogs with nonhematopoietic malignancies. Am J Vet Res 1997;58:277-81.
34. Noguchi Y, Nomura K, Yoshikawa T, et al. Role of insulin resistance in decreasing lipoprotein lipase activity in tumor-bearing rats. Surg Today 1996;26:271-5.
35. Svaninger G, Drott C, Lundholm K. Role of insulin in development of cancer cachexia in nongrowing sarcoma-bearing mice: special reference to muscle wasting. J Natl Cancer Inst 1987;78:943-50.
36. Cersosimo E, Pisters PW, Pesola G, et al. The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia. Surgery 1991;109:459-67.
37. Pearlstone DB, Wolf RF, Berman RS, Burt M, Brennan MF. Effect of systemic insulin on protein kinetics in postoperative cancer patients. Ann Surg Oncol 1994;1:321-32.
38. Ng EH, Rock CS, Lazarus DD, Stiaino-Coico L, Moldawer LL, Lowry SF. Insulin-like growth factor I preserves host lean tissue mass in cancer cachexia. Am J Physiol 1992;262:R426-31.
39. Bennegard K, Lundgren F, Lundholm K. Mechanisms of insulin resistance in cancer associated malnutrition. Clin Physiol 1986;6:539-47.
40. Lindmark L, Bennegard K, Eden E, Svaninger G, Ternell M, Lundholm K. Thermic effect and substrate oxidation in response to intravenous nutrition in cancer patients who lose weight. Ann Surg 1986;204:628-36.
41. Moller-Loswick AC, Zachrisson H, Hyltander A, Korner U, Matthews DE, Lundholm K. Insulin selectively attenuates breakdown of nonmyofibrillar proteins in peripheral tissues of normal men. Am J Physiol 1994;266:E645-52.
42. Lundholm K, Bennegard K, Eden E, Svaninger G, Emery PW, Rennie MJ. Efflux of 3-methylhistidine from the leg in cancer patients who experience weight loss. Cancer Res 1982;42:4807-11.
43. Vissing J, Haller RG. The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. N Engl J Med 2003;349:2503-9.
44. Lindholm E, Brevinge H, Bergh CH, Korner U, Lundholm K. Relationships between self-reported health related quality of life and measures of standardized exercise capacity and metabolic efficiency in a middle-aged and aged healthy population. Qual Life Res 2003;12:575-82.
45. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004;127:1044-50.
46. Maloney EK, McLaughlin JL, Dagdigian NE, et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003;63:5073-83.
47. Wang N, ThuraisingamT, Fallavollita L, Ding A, Radzioch D, Brodt P. The secretory leukocyte protease inhibitor is a type 1 insulin-like growth factor receptor-regulated protein that protects against liver metastasis by attenuating the host proinflammatory response. Cancer Res 2006;66:3062-70.
48. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66:8927-30.
49. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-61.
50. Ljungqvist O, Nygren J, Soop M, Thorell A. Metabolic perioperative management: novel concepts. Curr Opin Crit Care 2005;11:295-9.
51. Taleb S, Van Haaften R, Henegar C, et al. Micro-array profiling of human white adipose tissue after exogenous leptin injection. Eur J Clin Invest 2006; 36:153-63.